Company: SYRA
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-022023
Chunk: 2

Company: Syra Health Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 2
---
     
     489,839

    Research and development expenses 
     816  
     34,821  
     67,701 
     
     590,263

    Selling, general and administrative expenses 
     252,384  
     288,305  
     828,741 
     
     1,267,634

    Depreciation 
     5,396  
     25,541  
     18,171 
     
     55,460

    Total operating expenses 
     786,712  
     1,097,208  
     2,665,255 
     
     4,581,301

    Operating loss 
     (232,171) 
     (428,910) 
     (768,663)
     
     (3,263,217
    )

    Other income (expense): 

    Interest income 
     8,174  
     13,641  
     15,892 
     
     18,448

    Interest expense 
     (1,905) 
     (2,266) 
     (8,992)
     
     (10,072
    )
  
    Total other income (expense) 
     6,269  
     11,375  
     6,900 
     
     8,376

    Net loss 
    $(225,902) 
    $(417,535) 
    $(761,763)
     
    $(3,254,841
    )

    Weighted average common shares outstanding - basic and diluted 
     11,939,169  
     7,264,768  
     11,823,089 
     
     6,789,209

    Net loss per common share - basic and diluted 
    $(0.02) 
    $(0.06) 
    $(0.06)
     
    $(0.48
    )

See
accompanying notes to condensed unaudited financial statements.

F-2

SYRA
HEALTH CORP.

STATEMENTS
OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Deficit  
    (Def